Aglaia Management B.V.

Aglaia Oncology Funds invests in early-stage oncology drug development companies. The firm has a proven track record in selecting and maturing early-stage breakthrough inventions that have the potential to transform cancer treatment. The firm has been a pioneer in impact investing since its foundation in 2004. The firm developed together with Sinzer-Grant Thornton a tool to monitor the socio-economic impact of its investments in oncology biotech companies. The firm offers investors an opportunity to combine an attractive financial return with a meaningful impact on healthcare and society.